- Home
- HOOK vs DSS Comparison
HOOK vs DSS Comparison
Compare HOOK & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- DSS
- Stock Information
- Founded
- HOOK 2011
- DSS 1984
- Country
- HOOK United States
- DSS United States
- Employees
- HOOK N/A
- DSS N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- DSS Containers/Packaging
- Sector
- HOOK Health Care
- DSS Consumer Discretionary
- Exchange
- HOOK Nasdaq
- DSS Nasdaq
- Market Cap
- HOOK 9.3M
- DSS 8.9M
- IPO Year
- HOOK 2019
- DSS N/A
- Fundamental
- Price
- HOOK $1.25
- DSS $0.91
- Analyst Decision
- HOOK Buy
- DSS
- Analyst Count
- HOOK 4
- DSS 0
- Target Price
- HOOK $10.67
- DSS N/A
- AVG Volume (30 Days)
- HOOK 62.9K
- DSS 186.4K
- Earning Date
- HOOK 08-07-2025
- DSS 08-12-2025
- Dividend Yield
- HOOK N/A
- DSS N/A
- EPS Growth
- HOOK N/A
- DSS N/A
- EPS
- HOOK N/A
- DSS N/A
- Revenue
- HOOK $9,351,000.00
- DSS $20,180,000.00
- Revenue This Year
- HOOK N/A
- DSS N/A
- Revenue Next Year
- HOOK N/A
- DSS N/A
- P/E Ratio
- HOOK N/A
- DSS N/A
- Revenue Growth
- HOOK N/A
- DSS 12.88
- 52 Week Low
- HOOK $0.72
- DSS $0.72
- 52 Week High
- HOOK $6.77
- DSS $1.75
- Technical
- Relative Strength Index (RSI)
- HOOK 38.94
- DSS 49.41
- Support Level
- HOOK $1.23
- DSS $0.79
- Resistance Level
- HOOK $1.30
- DSS $1.03
- Average True Range (ATR)
- HOOK 0.06
- DSS 0.07
- MACD
- HOOK -0.03
- DSS -0.00
- Stochastic Oscillator
- HOOK 5.97
- DSS 52.46
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.